Abstracts tagged "antiphospholipid syndrome and prognostic factors"

Abstract Number: L7 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome without Anticoagulation: 0utcome of 50 Patients
Cécile Yelnik^1,2, Geoffrey Urbanski^1,3, Hélène Maillard^2,4, Aurélia Lanteri^1,2, Noémie Chanson^1,5, Chloé Stavris^1,3, Sandrine Morell-Dubois^1,3, David Launay^3,6,7, Sylvain Dubucquoi^6,7,8, Eric Hachulla^1,3,6, Pierre-Yves Hatron^1,3 and Marc Lambert^1,2, ¹Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ²Service de médecine interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ³Service de médecine interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, Lille, France, ⁴Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France, ⁵Hôpital Claude Huriez, Lille, France, ⁶EA 2686, Lille, Lille, France, ⁷Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ⁸Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France
Background/Purpose: Long-term anticoagulation is currently the standard treatment for arterial or venous antiphospholipid syndrome (APS). However, in daily clinical practice, the question of withdrawing anticoagulation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].